CORT

Insider Trades

Name	Value	Action	Price	Current Price
Guyer WilliamChief Development Officer $1.4M20k shares SellJun 2, 2026 $70.60 --
Maduck SeanSee Remarks $1.5M21.1k shares SellJun 1, 2026 $70.11 --
Mokari AtabakChief Financial Officer $2.8M40k shares SellJun 1, 2026 $70.00 --
Belanoff Joseph KDirector, Officer: Chief Executive Officer $895k12.8k shares SellJun 1, 2026 $69.74 --
Maduck SeanSee Remarks $278k3.9k shares SellJun 1, 2026 $70.75 --
Maduck SeanSee Remarks $3.6M54.6k shares SellMay 27, 2026 $65.37 --

News

zacks.comCORT Stock Rises 42% in a Month: Here's What You Should Knowzacks.comJun 8

gurufocus.comCorcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®gurufocus.comJun 6

businesswire.comCorcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®businesswire.comJun 6

fool.comHealthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotechfool.comJun 5

fool.comState Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?fool.comJun 4

Trade CORT

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.

CEO: Joseph K. Belanoff
IPO Date: Apr 14, 2004

Market Data

Open: $74.01
High: $77.62
Low: $73.62
Volume: 1M
52W High: $91.00
52W Low: $28.66

Valuation

Market Cap: $8.3B
Enterprise Value: $8.2B

Financials

Free Cash Flow: $142M
Revenue: $761M
Net Income: $100M
Cash: $120M
Debt: $6.1M

Events

EarningsJul 30

EPS est. 0.01227